Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on March 23, 2023, reporting an event that occurred on March 20, 2023. The filing addresses a change in the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance matters and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Lars Ekman, M.D., Ph.D. notified the Company of his decision to retire from the Board of Directors.
- The retirement is effective immediately after the 2023 Annual Meeting of Stockholders, currently scheduled for June 7, 2023.
- The departure is for personal reasons and is not related to any disagreement with the Company or its management regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Investor Verification Checklist
- Verify the date of the 2023 Annual Meeting of Stockholders to confirm the exact effective date of Dr. Ekman's retirement.
- Check subsequent filings to determine if a replacement director has been nominated or elected to fill the vacancy.
- Review the Company's proxy statement for the 2023 Annual Meeting for further details on board composition and governance.